Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12619001534178
Ethics application status
Approved
Date submitted
30/09/2019
Date registered
6/11/2019
Date last updated
29/08/2024
Date data sharing statement initially provided
6/11/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
A phase I/II double-blind, randomised controlled trial assessing effect of medicinal cannabis on quality of life and symptom control in advanced cancer.
Scientific title
A phase I/II double-blind, randomised controlled trial assessing effect of medicinal cannabis on quality of life and symptom control in advanced cancer.
Secondary ID [1] 299454 0
None
Universal Trial Number (UTN)
U1111-1241-2539
Trial acronym
RESONANCE
Linked study record
None

Health condition
Health condition(s) or problem(s) studied:
Advanced Cancer 314661 0
Palliative Care 314662 0
Condition category
Condition code
Cancer 312993 312993 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This is a combined Phase 1/2 study. Phase 1 (confirmation of dose finding and participation up to 56 days (up to 28 days screening and 28 days of investigational product administration)) was completed in 2020.

Phase 2 is addressing the primary endpoint and will last up to 85 days (up to 28 days' screening, 29 days of investigational product, End of Trial review 28 days after last dose of investigational product).

The Investigational Product is an oral liquid (oil) formulation of Medicinal Cannabis or Placebo, with doses between 0.25 mL and 1mL administered one to three times per day, administered orally via syringe, for a maximum of 29 days/1 month. The dose is commenced at 0.25mL once a day, and up-titrated daily based on symptom control and tolerance to a maximum daily dose of 1mL three times a day. Participants increase their dose by 0.25mL at each interval (e.g. morning/afternoon/evening) for symptom control. This is based on their own tolerability of the IP.
Intervention code [1] 315697 0
Treatment: Drugs
Comparator / control treatment
Placebo, oral liquid, administered one to three times a day, daily for a maximum of 85 days/3 months. The placebo will be composed of a medium-chain triglyceride (MCT) oil.
Control group
Placebo

Outcomes
Primary outcome [1] 321563 0
Phase 1 Primary Outcome (composite):
To determine the safety, tolerability, and dose range of the study drug by evaluating and characterising the pharmacokinetic profile of medicinal cannabis and active metabolites, analysis of dose-limiting toxicities, and adverse events.
Pharmacokinetic parameters being assessed include serum concentration of CBD002 and metabolites.
Dose-limiting toxicities and adverse events will be measured by CTCAE criteria which can be classified by clinical examination, laboratory findings or patient reported symptoms.
Timepoint [1] 321563 0
Baseline (pre-dose), and 1, 2, 4, and 8 hours post administration of study drug, done on Days 1, 8, 15, and 29 post initiation of Medicinal Cannabis/Placebo.
Primary outcome [2] 321564 0
Phase 2 Primary Outcome:
To determine the impact of medicinal cannabis on global quality of life, as measured by change in EORTC QLQ PAL-Q30 from baseline.
Timepoint [2] 321564 0
Day 29 post initiation of Medicinal Cannabis/Placebo.
Secondary outcome [1] 375358 0
Phase 1 Secondary Outcomes:
To test the feasibility of the objectives proposed in the Phase 2 study. This includes the impact of medicinal cannabis on global quality of life, pain, insomnia, nausea, anxiety and treatment satisfaction (please review secondary outcomes below for specifics of method of outcome assessment). Feasibility of the objectives will be assessed by
o Questionnaires understandable and acceptable to all participants
o The IP dosing uptitration schedule able to be followed by all participants
o Feasibility of self-administration of the IP
Timepoint [1] 375358 0
Day 29 post initiation of Medicinal Cannabis or Placebo.
Secondary outcome [2] 375359 0
Phase 2 Secondary Outcomes:
To determine impact of medicinal cannabis on global quality of life, as measured by EORTC QLQ PAL-Q30.
Timepoint [2] 375359 0
At Days 8 and 15 (+/- 3 days) post initiation of Medicinal Cannabis/Placebo
Secondary outcome [3] 375660 0
Phase 1 Secondary Outcome:
To undertake exploratory pharmacokinetics studies profiling the medicinal cannabis and active metabolites. Pharmacokinetic parameters being assessed include serum concentration of CBD002 and metabolites.
Timepoint [3] 375660 0
Day 29 post initiation of Medicinal Cannabis or Placebo.
Secondary outcome [4] 375661 0
Phase 2 Secondary Outcome:
To evaluate impact of medicinal cannabis on:
1) Pain (as measured by change in BPI-SF (Brief Pain Inventory – Short Form)),



Timepoint [4] 375661 0
At Days 8 and 29 (+/- 3 days) post initiation of Medicinal Cannabis/Placebo
Secondary outcome [5] 375662 0
Phase 2 Secondary Outcome:
To evaluate impact of medicinal cannabis on:
2) Anorexia (as measured by FAACT (Functional Assessment of Anorexia/Cachexia and weight)),
Timepoint [5] 375662 0
At Days 8 and 29 (+/- 3 days) post initiation of Medicinal Cannabis/Placebo
Secondary outcome [6] 375663 0
Phase 2 Secondary Outcome:
*To evaluate impact of medicinal cannabis on:
3) Anxiety (as measured by HADS (Hospital Anxiety and Depression Scale)),
Timepoint [6] 375663 0
At Days 8 and 29 (+/- 3 days) post initiation of Medicinal Cannabis/Placebo
Secondary outcome [7] 375664 0
Phase 2 Secondary Outcome:
*To evaluate impact of medicinal cannabis on:
4) Sleep (as measured by ISI (Insomnia Severity Index)),
Timepoint [7] 375664 0
At Days 8 and 29 (+/- 3 days) post initiation of Medicinal Cannabis/Placebo
Secondary outcome [8] 375665 0
Phase 2 Secondary Outcome:
*To evaluate impact of medicinal cannabis on:
5) Nausea as measured by a NRS (Numerical Rating Scale))
Timepoint [8] 375665 0
At Days 8 and 29 (+/- 3 days) post initiation of Medicinal Cannabis/Placebo
Secondary outcome [9] 375666 0
Phase 2:
To evaluate treatment satisfaction as measured by (TSQM) Treatment Satisfaction Questionnaire for Medication
Timepoint [9] 375666 0
At Day 29 (+/- 3 days) post initiation of Medicinal Cannabis/Placebo
Secondary outcome [10] 375667 0
Phase 2:
*To evaluate caregiver burden as measured by QOL (CQOL-C)
Timepoint [10] 375667 0
At Days 8 and 29 (+/- 3 days) post initiation of Medicinal Cannabis/Placebo
Secondary outcome [11] 375668 0
To determine the safety and optimal Phase 2 dose range of medicinal cannabis as measured by occurrence of DLTs and adverse events, clinically meaningful changes from baseline in clinical laboratory parameters. DLTs and adverse events will be assessed by standard CCTAE Criteria.
This is a composite outcome.
Timepoint [11] 375668 0
At Day 29 (+/- 3 days) post initiation of Medicinal Cannabis/Placebo

Eligibility
Key inclusion criteria
*Able to provide written informed consent and greater than or equal to 18 years of age.
*Willing and able to comply with all study requirements, including treatment, blood sampling and other assessments.
*Patients with incurable advanced cancer, of any histological subtype.
*Life expectancy greater than 2 months.
*ECOG 0-2
*Female patients of childbearing potential should have a negative pregnancy test within 72 hours prior to receiving the first dose of study medication and use a medically acceptable form of contraception.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Patients with recent change to systemic anticancer treatment (chemotherapy, immunotherapy, targeted therapy, hormonal therapy). The following time intervals are relative to the first day of study therapy:
• Commenced new anticancer treatment within the last 14 days
• Completed anticancer treatment <14 days ago
• Planning to receive new anticancer treatment in the next 30 days
2. Having current radiotherapy, completed radiotherapy <14 days prior to first day of study therapy, or planning to have radiotherapy in the next 30 days
3. Severe hepatic impairment, as defined by:
• aspartate aminotransferase (AST) >5 times upper limit of normal, or
• alanine aminotransferase (ALT) >5 times upper limit of normal
4. Conditions preventing adequate absorption of study drug (including difficulty swallowing medications, intestinal obstruction, inflammatory bowel condition, colitis)
5. Inadequate renal function, defined as eGFR <30ml/min (using CKD-EPI calculation)
6. Substance use disorder (ICD-10 criteria (abuse, dependence) to alcohol, opioids, benzodiazepines, or illicit stimulants
7. Current or recent use of cannabis within 30 days prior to study entry. Participants must return a negative cannabis urine test.
8. Prior clinically significant adverse reaction to cannabis or cannabinoid based medications.
9. Unwilling to avoid driving or operating machinery whilst on trial.
10. Prior hypersensitivity or intolerable adverse reaction to cannabis or cannabinoid based medications. Patients on strong CYP3A4 inducers or inhibitors, or on strong CYP2C19 inducers or inhibitors (refer to Appendix 3).
11. Psychiatric or neurodegenerative condition which in the opinion of the investigator may compromise patient safety.
12. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a highly effective and reliable means of contraception. Male participants must have been surgically sterilised or use a (double if required) barrier method of contraception.
13. Actively receiving a concurrent investigational product.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Participants are blinded to their treatment for the duration of the trial.
Phase
Phase 1 / Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
25/09/2020
Actual
25/09/2020
Date of last participant enrolment
Anticipated
30/09/2024
Actual
Date of last data collection
Anticipated
31/12/2024
Actual
Sample size
Target
119
Accrual to date
41
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 14917 0
Austin Health - Austin Hospital - Heidelberg
Recruitment hospital [2] 14918 0
Royal Melbourne Hospital - City campus - Parkville
Recruitment hospital [3] 14919 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment hospital [4] 14920 0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Recruitment postcode(s) [1] 28186 0
3084 - Heidelberg
Recruitment postcode(s) [2] 28187 0
3050 - Parkville
Recruitment postcode(s) [3] 28188 0
3000 - Melbourne
Recruitment postcode(s) [4] 28189 0
3065 - Fitzroy

Funding & Sponsors
Funding source category [1] 303955 0
Government body
Name [1] 303955 0
Victorian Cancer Agency
Country [1] 303955 0
Australia
Primary sponsor type
Other
Name
Olivia Newton-John Cancer Research Institute
Address
Level 5, ONJWRC , Austin Health
145 Studley Road
Heidelberg VIC 3065
Country
Australia
Secondary sponsor category [1] 304121 0
None
Name [1] 304121 0
Address [1] 304121 0
Country [1] 304121 0
Other collaborator category [1] 280981 0
Commercial sector/Industry
Name [1] 280981 0
Cann Group Limited
Address [1] 280981 0
4 Research Avenue, Bundoora,
Victoria 3083 Australia
Country [1] 280981 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 304455 0
Austin Health HREC
Ethics committee address [1] 304455 0
Ethics committee country [1] 304455 0
Australia
Date submitted for ethics approval [1] 304455 0
30/10/2019
Approval date [1] 304455 0
24/12/2019
Ethics approval number [1] 304455 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 97006 0
Prof Hui Gan
Address 97006 0
Medical Oncology, 145 Studley Road Heidelberg VIC 3084
Country 97006 0
Australia
Phone 97006 0
+61 3 9496 5000
Fax 97006 0
Email 97006 0
[email protected]
Contact person for public queries
Name 97007 0
Billy McMahon
Address 97007 0
Olivia Newton-John Cancer Research Institute
Level 5, ONJWRC
145 Studley Road
Heidelberg VIC 3084
Country 97007 0
Australia
Phone 97007 0
+61 3 9496 5000
Fax 97007 0
Email 97007 0
[email protected]
Contact person for scientific queries
Name 97008 0
Billy McMahon
Address 97008 0
Olivia Newton-John Cancer Research Institute
Level 5, ONJWRC
145 Studley Road
Heidelberg VIC 3084
Country 97008 0
Australia
Phone 97008 0
+61 3 9496 3573
Fax 97008 0
Email 97008 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Data will be pooled and presented as such.


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
5167Study protocol  [email protected] Contact ONJCRI directly
5168Informed consent form  [email protected] Contact ONJCRI directly
5169Ethical approval  [email protected] Contact ONJCRI directly



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.